187 related articles for article (PubMed ID: 18405179)
41. Demographic Patterns and Increasing Incidence of Cutaneous T-Cell Lymphoma in Louisiana.
Maghfour J; Gill F; Olson J; Guido N; Echuri H; Murina A
JAMA Oncol; 2022 Aug; 8(8):1218-1220. PubMed ID: 35708682
[TBL] [Abstract][Full Text] [Related]
42. Cutaneous T-cell lymphoma in Colorado 1974-1991.
Bunker JD; Freeman JH; Jester JD; Golitz LE
J Dermatol; 1991 Jul; 18(7):369-76. PubMed ID: 1791245
[No Abstract] [Full Text] [Related]
43. Antiidiotype (Ab2) vaccine therapy for cutaneous T-cell lymphoma.
Chatterjee M; Mrozek E; Vaickus L; Oseroff A; Stoll H; Russell D; Kohler H; Foon KA
Ann N Y Acad Sci; 1993 Aug; 690():376-7. PubMed ID: 8368761
[No Abstract] [Full Text] [Related]
44. Cutaneous T cell lymphomas.
Bunn PA
BMJ; 1994 Feb; 308(6928):551-2. PubMed ID: 8031362
[No Abstract] [Full Text] [Related]
45. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018.
Gilson D; Whittaker SJ; Child FJ; Scarisbrick JJ; Illidge TM; Parry EJ; Mohd Mustapa MF; Exton LS; Kanfer E; Rezvani K; Dearden CE; Morris SL
Br J Dermatol; 2019 Mar; 180(3):496-526. PubMed ID: 30561020
[No Abstract] [Full Text] [Related]
46. Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2.
Baccard M; Marolleau JP; Rybojad M
Arch Dermatol; 1997 May; 133(5):656. PubMed ID: 9158425
[No Abstract] [Full Text] [Related]
47. Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis.
Cai ZR; Chen ML; Weinstock MA; Kim YH; Novoa RA; Linos E
JAMA Oncol; 2022 Nov; 8(11):1690-1692. PubMed ID: 36048455
[TBL] [Abstract][Full Text] [Related]
48. Second neoplasms associated with primary cutaneous lymphomas.
Gómez Sánchez ME; Rodríguez Vázquez M; Mollejo Villanueva M
An Bras Dermatol; 2019; 94(6):759-761. PubMed ID: 31789255
[No Abstract] [Full Text] [Related]
49. Epidemiological and clinical features of patients diagnosed with cutaneous T-cell lymphomas in a Spanish tertiary care hospital.
Cieza-Díaz DE; Conde-Montero E; Menarguez-Palanca J; Longo-Imedio I
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):e150-e153. PubMed ID: 27518589
[No Abstract] [Full Text] [Related]
50. Cutaneous dissemination of nasal NK/T-cell lymphoma in a young girl.
Sandner A; Helmbold P; Winkler M; Gattenlöhner S; Müller-Hermelink HK; Holzhausen HJ
Clin Exp Dermatol; 2008 Aug; 33(5):615-8. PubMed ID: 18616730
[TBL] [Abstract][Full Text] [Related]
51. Interferon alfa-induced interstitial pneumonitis in a patient with cutaneous T-cell lymphoma.
Nouri K; Valor R; Rodriguez FM; Kerdel FA
J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):269-70. PubMed ID: 8708036
[No Abstract] [Full Text] [Related]
52. Infantile-onset cutaneous T-cell lymphoma.
Tsianakas A; Kienast AK; Hoeger PH
Br J Dermatol; 2008 Dec; 159(6):1338-41. PubMed ID: 18717674
[TBL] [Abstract][Full Text] [Related]
53. Proceedings of the International Consensus Conference on Cutaneous T-cell Lymphoma (CTCL) Treatment Recommendations. Boston, Massachusetts, Oct. 1 and 2, 1994.
Demierre MF; Foss FM; Koh HK
J Am Acad Dermatol; 1997 Mar; 36(3 Pt 1):460-6. PubMed ID: 9091480
[TBL] [Abstract][Full Text] [Related]
54. Splenectomy followed by local injections of interferon-alpha is effective for treating cutaneous-type adult T-cell leukaemia/lymphoma.
Takemori N; Hirai K; Onodera R; Saito N; Watanabe S; Namiki M
Br J Dermatol; 1993 Dec; 129(6):746-7. PubMed ID: 8286266
[No Abstract] [Full Text] [Related]
55. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.
Bisaccia E; Vonderheid EC; Geskin L
Br J Dermatol; 2009 Jul; 161(1):167-9. PubMed ID: 19298276
[TBL] [Abstract][Full Text] [Related]
56. Cutaneous lymphomas management during COVID-19 pandemic.
Vitiello P; Sica A; Ronchi A; Pastore F; Casale B; Argenziano G
Ital J Dermatol Venerol; 2021 Apr; 156(2):248-249. PubMed ID: 33084270
[No Abstract] [Full Text] [Related]
57. The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas.
Bunn PA; Norris DA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):209S-212S. PubMed ID: 1701807
[No Abstract] [Full Text] [Related]
58. Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas.
Dummer R; Rozati S; Guenova E; Cozzio A
Future Oncol; 2013 Aug; 9(8):1061-4. PubMed ID: 23902236
[No Abstract] [Full Text] [Related]
59. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
Magro CM; Dyrsen ME
J Cutan Pathol; 2008 Nov; 35(11):1040-9. PubMed ID: 18681860
[TBL] [Abstract][Full Text] [Related]
60. Epidemiology of cutaneous lymphoma.
Vermeer M
Br J Dermatol; 2021 Jun; 184(6):993-994. PubMed ID: 33656170
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
